Computational characterization of the selective inhibition of human norepinephrine and serotonin transporters by an escitalopram scaffold.

Human norepinephrine and serotonin transporters (hNET and hSERT) are closely related monoamine transporters (MATs) that regulate neurotransmitter signaling in neurons and are primary targets for a wide range of therapeutic drugs used in the treatment of mood disorders. The subtle modifications of an escitalopram scaffold exhibit distinct selective inhibition profiles of hNET and hSERT. However, the structural details of escitalopram scaffold binding to hSERT and (or) hNET are poorly understood and still remain a great challenge. In this work, on the basis of more recently solved X-ray crystallographic structure of hSERT in complex with escitalopram, 3 μs long all-atom MD simulations and binding free energy calculations via MM/GB(PB)SA, thermodynamic integration (TI) and MM/3D-RISM methods were performed to reproduce experimental free energies. And both MM/GBSA and TI have a high correlation coefficient (R2 = 0.95 and 0.96, respectively) between the relative binding free energies of the calculated and experimental values. Furthermore, MM/GBSA per-residue energy decomposition, molecular interaction fingerprints and thermodynamics-structure relationship analysis were employed to investigate and characterize the selectivity of the escitalopram scaffold with three modifications (escitalopram, ligand10 and talopram) to hNET and hSERT. As a result, 4 warm spots (A73, Y151, A477 and I481) in hNET and 4 warm spots (A96, A173, T439 and L443) in hSERT were thus discovered to exert a pronounced effect on the selective inhibition of hNET and hSERT by the studied ligands. These simulation results would provide great insight into the design of inhibitors with the desired selectivity to hNET and hSERT, thus further promoting the research of more efficacious antidepressants.

[1]  B. Schiøtt,et al.  Molecular Basis for Selective Serotonin Reuptake Inhibition by the Antidepressant Agent Fluoxetine (Prozac) , 2014, Molecular Pharmacology.

[2]  Benoît Roux,et al.  Solvation thermodynamics: An approach from analytic temperature derivatives , 1990 .

[3]  Shuang Li,et al.  SVM-Prot 2016: A Web-Server for Machine Learning Prediction of Protein Functional Families from Sequence Irrespective of Similarity , 2016, PloS one.

[4]  A. Sandelin,et al.  Interaction of Antidepressants with the Serotonin and Norepinephrine Transporters , 2012, The Journal of Biological Chemistry.

[5]  J. Madura,et al.  Monoamine Transporter Structure, Function, Dynamics, and Drug Discovery: A Computational Perspective , 2012, The AAPS Journal.

[6]  Feng Zhu,et al.  Differentiating Physicochemical Properties between Addictive and Nonaddictive ADHD Drugs Revealed by Molecular Dynamics Simulation Studies. , 2017, ACS chemical neuroscience.

[7]  Hyeon Joo,et al.  OPM database and PPM web server: resources for positioning of proteins in membranes , 2011, Nucleic Acids Res..

[8]  Tingting Fu,et al.  Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics , 2017, Nucleic Acids Res..

[9]  Darrin M York,et al.  A GPU-Accelerated Parameter Interpolation Thermodynamic Integration Free Energy Method. , 2018, Journal of chemical theory and computation.

[10]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[11]  Youyong Li,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. , 2014, Physical chemistry chemical physics : PCCP.

[12]  Sunhwan Jo,et al.  CHARMM‐GUI Membrane Builder toward realistic biological membrane simulations , 2014, J. Comput. Chem..

[13]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[14]  Lu Huang,et al.  Update of TTD: Therapeutic Target Database , 2009, Nucleic Acids Res..

[15]  E. Gouaux,et al.  Structural basis for action by diverse antidepressants on biogenic amine transporters , 2013, Nature.

[16]  Xavier Robert,et al.  Deciphering key features in protein structures with the new ENDscript server , 2014, Nucleic Acids Res..

[17]  Feng Zhu,et al.  Identification of novel immune‐relevant drug target genes for Alzheimer's Disease by combining ontology inference with network analysis , 2018, CNS neuroscience & therapeutics.

[18]  Daniel J. Sindhikara,et al.  A 3D‐RISM/RISM study of the oseltamivir binding efficiency with the wild‐type and resistance‐associated mutant forms of the viral influenza B neuraminidase , 2016, Protein science : a publication of the Protein Society.

[19]  Jacob Andersen,et al.  From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies. , 2008, Journal of medicinal chemistry.

[20]  Andriy Kovalenko,et al.  An MM/3D-RISM approach for ligand binding affinities. , 2010, The journal of physical chemistry. B.

[21]  G. Klebe.  Applying thermodynamic profiling in lead finding and optimization , 2015, Nature Reviews Drug Discovery.

[22]  Michelle L Coote,et al.  Molecular dynamics-driven drug discovery: leaping forward with confidence. , 2017, Drug discovery today.

[23]  L. Iversen.  Neurotransmitter transporters: fruitful targets for CNS drug discovery , 2000, Molecular Psychiatry.

[24]  Feng Zhu,et al.  Comparison of computational model and X-ray crystal structure of human serotonin transporter: potential application for the pharmacology of human monoamine transporters , 2017 .

[25]  F Zhu,et al.  Homology-free prediction of functional class of proteins and peptides by support vector machines. , 2008, Current protein & peptide science.

[26]  Feng Zhu,et al.  Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study , 2016, Scientific Reports.

[27]  Feng Zhu,et al.  Discovery of the Consistently Well-Performed Analysis Chain for SWATH-MS Based Pharmacoproteomic Quantification , 2018, Front. Pharmacol..

[28]  P. Kollman,et al.  Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .

[29]  U. Gether,et al.  SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation , 2011, Pharmacological Reviews.

[30]  Tudor I. Oprea,et al.  A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.

[31]  H. G. Petersen.  Accuracy and efficiency of the particle mesh Ewald method , 1995 .

[32]  Robert Abel,et al.  Advancing Drug Discovery through Enhanced Free Energy Calculations. , 2017, Accounts of chemical research.

[33]  Barry Honig,et al.  Identification of a chloride ion binding site in Na+/Cl−-dependent transporters , 2007, Proceedings of the National Academy of Sciences.

[34]  Martti T. Tammi,et al.  Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting , 2008 .

[35]  Randy D. Blakely,et al.  Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter , 1991, Nature.

[36]  Feng Zhu,et al.  Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder. , 2018, Physical chemistry chemical physics : PCCP.

[37]  Jennifer L. Knight,et al.  Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. , 2015, Journal of the American Chemical Society.

[38]  Feng Zhu,et al.  Assessing the Performances of Protein Function Prediction Algorithms from the Perspectives of Identification Accuracy and False Discovery Rate , 2018, International journal of molecular sciences.

[39]  J. Foster,et al.  SLC6 transporters: structure, function, regulation, disease association and therapeutics. , 2013, Molecular aspects of medicine.

[40]  Yuzong Chen,et al.  What Contributes to Serotonin-Norepinephrine Reuptake Inhibitors' Dual-Targeting Mechanism? The Key Role of Transmembrane Domain 6 in Human Serotonin and Norepinephrine Transporters Revealed by Molecular Dynamics Simulation. , 2018, ACS chemical neuroscience.

[41]  Feng Xu,et al.  Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information , 2015, Nucleic Acids Res..

[42]  Feng Zhu,et al.  Prediction of the binding mode and resistance profile for a dual-target pyrrolyl diketo acid scaffold against HIV-1 integrase and reverse-transcriptase-associated ribonuclease H. , 2018, Physical chemistry chemical physics : PCCP.

[43]  Martti T Tammi,et al.  What Are Next Generation Innovative Therapeutic Targets? Clues from Genetic, Structural, Physicochemical, and Systems Profiles of Successful Targets , 2009, Journal of Pharmacology and Experimental Therapeutics.

[44]  D. Case,et al.  Simple electrolyte solutions: comparison of DRISM and molecular dynamics results for alkali halide solutions. , 2013, The Journal of chemical physics.

[45]  E. Gouaux,et al.  X-ray structures and mechanism of the human serotonin transporter , 2016, Nature.

[46]  P. Gillman.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated , 2007, British journal of pharmacology.

[47]  Jens Roat Kultima,et al.  Potential of fecal microbiota for early‐stage detection of colorectal cancer , 2014 .

[48]  M. Barnes,et al.  Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function , 2009, Molecular Psychiatry.

[49]  Weiwei Xue,et al.  The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective , 2016, PloS one.

[50]  M. Raggi,et al.  Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. , 2012, Current medicinal chemistry.

[51]  Tai-Sung Lee,et al.  Toward Fast and Accurate Binding Affinity Prediction with pmemdGTI: An Efficient Implementation of GPU-Accelerated Thermodynamic Integration. , 2017, Journal of chemical theory and computation.

[52]  Tingjun Hou,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 7. Entropy effects on the performance of end-point binding free energy calculation approaches. , 2018, Physical chemistry chemical physics : PCCP.

[53]  P. Bandyopadhyay,et al.  Comparison of molecular mechanics-Poisson-Boltzmann surface area (MM-PBSA) and molecular mechanics-three-dimensional reference interaction site model (MM-3D-RISM) method to calculate the binding free energy of protein-ligand complexes: Effect of metal ion and advance statistical test , 2018 .

[54]  Benjamin D. Madej,et al.  Lipid14: The Amber Lipid Force Field , 2014, Journal of chemical theory and computation.

[55]  S. Toubro,et al.  Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters , 2011, Proceedings of the National Academy of Sciences.

[56]  F. Hirata,et al.  Predicting the binding free energy of the inclusion process of 2-hydroxypropyl-β-cyclodextrin and small molecules by means of the MM/3D-RISM method , 2016, Journal of physics. Condensed matter : an Institute of Physics journal.

[57]  Laura Pérez-Benito,et al.  Application of Free Energy Perturbation for the Design of BACE1 Inhibitors , 2016, J. Chem. Inf. Model..

[58]  W. C. Still,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999 .

[59]  Birgit Schiøtt,et al.  Monoamine transporters: insights from molecular dynamics simulations , 2015, Front. Pharmacol..

[60]  Dan Li,et al.  Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein-protein binding free energies and re-rank binding poses generated by protein-protein docking. , 2016, Physical chemistry chemical physics : PCCP.

[61]  Feng Zhu,et al.  Clinical Success of Drug Targets Prospectively Predicted by In Silico Study. , 2017, Trends in pharmacological sciences.

[62]  Feng Xu,et al.  Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. , 2015, Pharmacological research.

[63]  William L Jorgensen,et al.  Efficient drug lead discovery and optimization. , 2009, Accounts of chemical research.

[64]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[65]  Feng Zhu,et al.  Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD. , 2017, Biochimica et biophysica acta. General subjects.

[66]  Feng Zhu,et al.  Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. , 2016, Physical chemistry chemical physics : PCCP.

[67]  D. Case,et al.  Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.

[68]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[69]  Thomas E. Cheatham,et al.  Molecular Dynamics Simulations of the Dynamic and Energetic Properties of Alkali and Halide Ions Using Water-Model-Specific Ion Parameters , 2009, The journal of physical chemistry. B.

[70]  Charles L. Brooks,et al.  Detailed considerations for a balanced and broadly applicable force field: A study of substituted benzenes modeled with OPLS‐AA , 2005, J. Comput. Chem..

[71]  Dima Kozakov,et al.  Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery. , 2015, Trends in pharmacological sciences.

[72]  C. Sánchez,et al.  Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. , 2015, Biochemical pharmacology.

[73]  P Reddanna,et al.  Free energy calculations to estimate ligand-binding affinities in structure-based drug design. , 2014, Current pharmaceutical design.

[74]  Didier Rognan,et al.  Encoding Protein-Ligand Interaction Patterns in Fingerprints and Graphs , 2013, J. Chem. Inf. Model..

[75]  Bo Li,et al.  NOREVA: normalization and evaluation of MS-based metabolomics data , 2017, Nucleic Acids Res..

[76]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[77]  C. Nemeroff,et al.  Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine , 2001, Biological Psychiatry.

[78]  Xiao Hua Ma,et al.  Drug Discovery Prospect from Untapped Species: Indications from Approved Natural Product Drugs , 2012, PloS one.

[79]  I. Bahar,et al.  Normal mode analysis of biomolecular structures: functional mechanisms of membrane proteins. , 2010, Chemical reviews.

[80]  Eric Gouaux,et al.  X-ray structure of dopamine transporter elucidates antidepressant mechanism , 2013, Nature.

[81]  B. Brooks,et al.  An analysis of the accuracy of Langevin and molecular dynamics algorithms , 1988 .

[82]  Jack Snoeyink,et al.  Nucleic Acids Research Advance Access published April 22, 2007 MolProbity: all-atom contacts and structure validation for proteins and nucleic acids , 2007 .

[83]  Carlos Simmerling,et al.  Three-dimensional molecular theory of solvation coupled with molecular dynamics in Amber. , 2010, Journal of chemical theory and computation.

[84]  P. Saltiel,et al.  Major depressive disorder: mechanism-based prescribing for personalized medicine , 2015, Neuropsychiatric disease and treatment.

[85]  Feng Zhu,et al.  Performance Evaluation and Online Realization of Data-driven Normalization Methods Used in LC/MS based Untargeted Metabolomics Analysis , 2016, Scientific Reports.

[86]  Tingjun Hou,et al.  Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..

[87]  Xingyu Wang,et al.  A Comparative Insight into Amprenavir Resistance of Mutations V32I, G48V, I50V, I54V, and I84V in HIV-1 Protease Based on Thermodynamic Integration and MM-PBSA Methods , 2015, J. Chem. Inf. Model..

[88]  Z. R. Li,et al.  Update of PROFEAT: a web server for computing structural and physicochemical features of proteins and peptides from amino acid sequence , 2006, Nucleic Acids Res..

[89]  Christopher W Murray,et al.  Predicting "Hot" and "Warm" Spots for Fragment Binding. , 2017, Journal of medicinal chemistry.

[90]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[91]  F. Hirata,et al.  Three-dimensional density profiles of water in contact with a solute of arbitrary shape: a RISM approach , 1998 .

[92]  Feng Zhu,et al.  Exploring the Binding Mechanism of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators in Clinical Trials by Molecular Dynamics Simulations. , 2018, ACS chemical neuroscience.

[93]  Feng Zhu,et al.  Identification of dual active agents targeting 5-HT1A and SERT by combinatorial virtual screening methods. , 2015, Bio-medical materials and engineering.

[94]  Gilles Marcou,et al.  Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..